45d agoBarron'sBEARISH 34General
Archived explainer. For the current picture see today's ARWR page.
Why Is ARROWHEAD PHARMACEUT (ARWR) Stock Down Today?
By the Top Tier Newswire AI Desk · September 16, 2026 at 11:05 AM ET · reviewed against 4 wire stories
ARROWHEAD PHARMACEUT (ARWR) is down -5.80% in the latest session. Our newswire has captured 4 stories on ARWR across 4 sources in the last 36 hours, with AI sentiment reading mixed (avg 49/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why ARWR stock is down today
Arrowhead Pharmaceuticals stock fell 5.80% to $66.57 in early trading on Monday after the release of interim clinical data for its first dual-functional RNAi therapeutic. The stock opened higher but quickly reversed course, reaching a session low of $66.50 before closing the session at $66.63. The decline marked one of the stock’s worst days in over a year, despite the positive data showing significant reductions in key cholesterol markers.
What Happened
The stock’s decline followed the announcement of interim topline clinical data for Arrowhead’s Phase 1/2a study of its dual-functional RNAi therapeutic for mixed hyperlipidemia. The data showed mean maximal reductions of 88% in APOC3, 54% in LDL-C, and 73% in triglycerides. Despite these positive results, the stock struggled as the market appeared to interpret the news as a "sell the news" event. The company also presented at the Morgan Stanley 24th Annual Global Healthcare Conference, but the timing coincided with a broader market selloff and rising 10-year yields, which added pressure to the stock.
What The Data Shows
The stock opened with a 0.7% gap up from the previous close but quickly reversed course, hitting a low near $66.50 by midday. Trading volume was 1.2 million shares, which is 0.6 times the 3-month average, suggesting limited follow-through. Over the past 8 sessions, the stock has fallen 14.5% from $85.40 to $73.04. Meanwhile, sentiment has deteriorated, with the 7-day average at 50/100 compared to a 30-day average of 57/100. Recent insider transactions also showed two directors selling shares totaling $1.2 million in late August.
What To Watch
Arrowhead Pharmaceuticals has no upcoming earnings report scheduled. Investors will likely monitor the breadth of coverage and market reaction to the new clinical data in the coming days.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
ARWR by the numbers
Last: $66.57Session: -5.80%7 sessions: -23.80%Coverage: 4 stories / 4 sourcesAI sentiment: 49/100 (mixed)Mkt cap: $11.4B52w: $28.12 to $95.49
The headlines behind the move
45d agoStocktwits NewsBEARISH 38General
ARWR Stock On Track For Worst Day In Over A Year Despite Positive Early-Stage Data For Cholesterol Drug — Retail Dismisses ‘Sell The News’ Reaction
ARWR had already run hard into the catalyst and remains far above last year’s levels after a 52-week high near $95 in July.
45d agoSeeking AlphaBULLISH 56General
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Arrowhead Pharmaceuticals, Inc. (ARWR) Morgan Stanley 24th Annual Global Healthcare Conference September 15, 2026 11:30 AM EDTCompany ParticipantsDr.
46d agoStockTitanBULLISH 67Product/PR
Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
The Phase 1/2a study also found mean maximal reductions of 88% in APOC3, 54% in LDL-C and 73% in triglycerides; multiple-dose safety testing continues.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on ARWR: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier ARWR move explainers: 2026-09-16 · 2026-09-15 · 2026-09-08 · 2026-08-31